



CYFRA 21-1™+ TUMOR MARKER ASSAY FOR THE MEASUREMENT OF CYTOKERATIN 19 FRAGMENTS

The Fujirebio Diagnostics, Inc. (FDI) Cyfra 21-1 tumor marker assay is used for the quantitative measurement of Cytokeratin 19 fragments in serum of patients with squamous cell carcinoma of the lungs.

■ Antibody/Antigen Components

The assay utilizes KS19.1 and BM19.21 antibodies in a forward sandwich format.

■ Quality Manufacturing


The Cyfra 21-1 Assay is manufactured in a proven high-quality process that is ISO 9001 certified.

Publications:

1. Pujol, J.L., et al: "Les marqueurs seriques des cancers bronchiques," *Medecine et Hygiene*, (1992).
2. Pujol, J.L., et al: "Serum Fragment of cytokeratin subunit 19 measured by Cyfra 21-1 immunoradiometric assay as a marker of lung cancer." *Cancer Research*, (1993).

*Not for sale in the United States.

CYFRA 21-1



FDI: THE TRUSTED NAME IN ONCOLOGY DIAGNOSTICS

In the field of oncology diagnostics, Fujirebio Diagnostics, Inc. (FDI) is the name people trust. Formerly Centocor Diagnostics, we pioneered the development of monoclonal antibody technology. Today, FDI is still the unparalleled leader in tumor marker assays worldwide, with innovative products that are unmatched in quality and dependability. FDI's extensive menu of diagnostic products sets the standard for excellence:

- Supported by thousands of peer-reviewed articles
- Endorsed by prestigious academic institutions and medical centers worldwide
- Proven manufacturing process and ISO 9001 certified quality system
- Distributed worldwide by leading healthcare organizations

FDI's Tumor Marker Assays include:

CA 125II™* (Ovarian Cancer) – Used for the quantitative determination of OC 125-defined antigen in serum of women with primary epithelial invasive ovarian cancer, excluding those with cancer of low malignant potential.

CA 19-9™* (Pancreatic Cancer) – Used for the serial measurement of CA 19-9 to aid in the management of patients diagnosed with cancers of the exocrine pancreas.

CA 15-3®* (Breast Cancer) – Used for the quantitative determination of DF3-defined antigen in serum or plasma of patients previously treated for stage II or stage III breast cancer.

CYFRA 21-1™* - FOR RESEARCH USE ONLY - The CYFRA 21-1 assay utilizes two antibodies, KS 19.1 and BM19.21 to measure the elevated levels of cytokeratin 19 fragments in serum.

CA 72-4®* - FOR RESEARCH USE ONLY - CA 72-4 is an *in vitro* test for research use only that quantitatively measures TAG-72 in blood and serum.

Other Diagnostic Products:

FITC Anti-Rabies Monoclonal Globulin – Used in the direct fluorescent antibody procedure for the *in vitro* detection of rabies in brains and submaxillary glands.

For more information, call +1.610.240.3800 or visit www.fdi.com

* These products are registered in compliance with the European **CE** mark.

+ Not for distribution in the United States.

Fujirebio Diagnostics
201 Great Valley Parkway
Malvern, PA 19355

610.240.3800
610.240.3825 fax
www.fdi.com

LEADERSHIP DEPENDABILITY INNOVATION